Adempas 2.5 mg (Riociguat TABLET) 2.5 MG

ADEMPAS 2.5 MG tablets contain riociguat, a medication used to treat certain conditions related to blood vessel function. This oral tablet is manufactured by Bayer Inc. in Canada.

Strength

2.5 MG

Pack Size

Manufacturer / TM Owner

BAYER INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ADEMPAS 2.5 MG tablets are generally used to improve exercise capacity in adults with specific conditions affecting blood vessel function. Riociguat, the active ingredient, is often prescribed for conditions that involve narrowing or blockage of the blood vessels. What is ADEMPAS used for? It is primarily used to help manage symptoms related to impaired blood flow.

Side Effects

Common effects of ADEMPAS 2.5 MG tablets may include headaches, dizziness, and nausea. Some users might experience low blood pressure or shortness of breath. These effects can vary from person to person and are not experienced by everyone.

Precautions & Warnings

ADEMPAS 2.5 MG tablets should be handled with care, especially if you have a history of low blood pressure or bleeding disorders. It is important to follow the advice of a healthcare professional regarding the use of this medication. Always store the tablets in a cool, dry place away from direct sunlight.

Avoid Interactions

ADEMPAS 2.5 MG tablets may interact with certain medications, including those that affect blood pressure or blood clotting. It is advisable to inform your healthcare provider about all the medications you are taking to avoid potential interactions. Alcohol and other substances that affect blood pressure should be used with caution.

Frequently Asked Questions

ADEMPAS 2.5 MG tablets are used to improve exercise capacity in adults with conditions related to blood vessel function.

ADEMPAS 2.5 MG tablets should be stored in a cool, dry place away from direct sunlight.

Common effects may include headaches, dizziness, and nausea. Some users might experience low blood pressure or shortness of breath.

Yes, ADEMPAS may interact with medications that affect blood pressure or blood clotting. Always consult a healthcare professional.

ADEMPAS is available in different strengths, including 2.5 MG. Check with your healthcare provider for the appropriate strength.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.